Why the study?
Does alprenolol reduce cardiac biomarker levels and estimated infarct size in patients with acute myocardial infarction?
Does alprenolol reduce cardiac biomarker levels and estimated infarct size in patients with acute myocardial infarction?
Early beta-blockade with alprenolol in acute myocardial infarction reduces cardiac biomarker release, providing indirect evidence of reduced infarct size.
Answers are grounded in this paper and cite their sources.
Early alprenolol limits infarct size in AMI; confirms beta-blockade benefit on biomarker release.
In a group of 37 patients with definite acute myocardial infarction (AMI) allocated to treatment with either alprenolol (n = 20) or placebo (n = 17) serial determinations of concentrations in serum of myoglobin (S-Mb), creatine kinase (S-CK), aspartate aminotransferase (S-ASAT) and lactate dehydrogenase (S-LDH) were performed. The median peak levels of S-Mb, S-CK and S-LDH were significantly (P less than 0.05) lower among patients treated with alprenolol. The median of the estimated infarct size based on S-CK curves was also significantly (P less than 0.01) lower in the alprenolol group. There was no significant difference between the estimated infarct size based on S-Mb values in the two groups. It is concluded that the present study provides indirect evidence for the assumption that early beta-blockade in AMI can reduce infarct size.
No takes yet. Share an insight, caveat, or question.
Pedersen et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: